Results 231 to 240 of about 1,048,377 (295)

Correction: Soluble fms-like tyrosine kinase-1 and peripartum cardiomyopathy: an exploratory meta-analysis of association and diagnostic performance. [PDF]

Front Cardiovasc Med
Dewi TI, Kamarullah W, Prameswari HS, Achmad C, Anwar R, Oceandy D, Wirakusumah FF.   +6 more
europepmc   +1 more source

CD14 Plays a Critical Role in Pain and Inflammation Across Multiple Models of Post‐traumatic Osteoarthritis

Arthritis &Rheumatology, EarlyView.
Objective We employed global genetic deletion of CD14 and intra‐articular CD14 blockade across multiple murine osteoarthritis (OA) models that vary in severity of pathology and rate of progression to test the hypothesis that CD14 inhibition attenuates synovial inflammation and associated pain during disease progression.
Kevin G. Burt, Sanique M. South, Natalie S. Adamczyk, Vu Nguyen, Shingo Ishihara, Cheng Zhou, Kate L. Sharp, Sung Y. Kim, Anna E. Rapp, Baofeng Hu, Lance A. Murphy, Li‐Yin Hung, De'Broski Herbert, Joshua F. Baker, Robert L. Mauck, Timothy M. Griffin, Anne‐Marie Malfait, Rachel E. Miller, Carla R. Scanzello   +18 more
wiley   +1 more source

Bruton's tyrosine kinase inhibitor BTKi-2 inhibits mpox virus and vaccinia virus infection. [PDF]

Virol Sin
Yang C, Zhao R, Huo S, Zhang Y, Feng J, Gong M, Zhu L, Zhang C, Zhang L, Xue J, Zhang R, Wang Q, Ding Q.   +12 more
europepmc   +1 more source

The DDR1 Tyrosine Kinase Promotes Th17 Cell Migration in Three-Dimensional Collagen and into the Joints During Inflammatory Arthritis. [PDF]

Int J Mol Sci
Hamoudi C, Toghi M, Lashgari A, Aoudjit F.   +3 more
europepmc   +1 more source

Impact of Selective Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) on Molecular Pathways and Correlated Clinical Response in Patients With Active Psoriatic Arthritis. [PDF]

ACR Open Rheumatol
Choudhury A, Cheng J, Tang J, Kumar S, Saha B, Arunachalam V, Hong T, Mark E, Wennbo H, McInnes IB.   +9 more
europepmc   +1 more source

Case Report: Tyrosine kinase inhibitors in ROS1-rearranged and granulocyte colony-stimulating factor-producing lung squamous cell carcinoma. [PDF]

Front Oncol
Li R, Zhang S, Liu Z, Wu X.
europepmc   +1 more source

Retraction: Nintedanib, a triple tyrosine kinase inhibitor, attenuates renal fibrosis in chronic kidney disease. [PDF]

Clin Sci (Lond)
Zhuang S, Liu F, Wang L, Qi H, Wang J, Wang Y, Jiang W, Xu L, Liu N.   +8 more
europepmc   +1 more source

A Novel Tyrosine Kinase Axis in Innate Immune Signaling. [PDF]

Viruses
Das S, Sengupta P, Veleeparambil M, Chattopadhyay S.   +3 more
europepmc   +1 more source

Targeting CBL ubiquitin ligase activation to downregulate tyrosine kinase signalling

Tench AJ, Martin CE, Simpson CD, Wybenga-Groot LE, Ly D, Fladd C, Elgie MH, Ahmed SF, Belizaire R, Huang DT, Gingras A, McGlade CJ.   +11 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Tyrosine Kinase Inhibitors

Current Cancer Drug Targets, 2010
Over the last ten years, several new and therapeutically relevant cancer drugs targeting tyrosine kinases signaling pathways have been developed. Tyrosine kinase inhibitors (TKIs) are a pharmaceutical class of small molecules, orally available, well-tolerated, worldwide approved drugs for the treatment of several neoplasms, including lung, breast ...
NATOLI, Clara, Perrucci Bruno, Perrotti Francesca, Falchi Lorenzo, IACOBELLI, Stefano, Consorzio Interuniversitario Nazionale per Bio Oncologia   +5 more
openaire   +3 more sources